

Dirk Schadendorf

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8868225/dirk-schadendorf-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

541 papers	80,690 citations	107 h-index	281 g-index
592 ext. papers	99,854 ext. citations	9 avg, IF	7.39 L-index

#	Paper	IF	Citations
541	PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.. <i>Future Oncology</i> , 2022 ,	3.6	2
540	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101601	2.2	10
539	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.. <i>New England Journal of Medicine</i> , 2022 , 386, 24-34	59.2	88
538	Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.. <i>Cancer Imaging</i> , 2022 , 22, 11	5.6	0
537	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101701	2.2	2
536	Management of partial and non-responding cutaneous squamous cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 , 36 Suppl 1, 29-34	4.6	0
535	Prognostic and predictive value of Eblockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. <i>European Journal of Cancer</i> , 2022 , 165, 97-112	7.5	0
534	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	40	18
533	MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.. <i>European Journal of Cancer</i> , 2022 , 166, 24-32	7.5	1
532	Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.. <i>European Journal of Cancer</i> , 2022 , 166, 60-72	7.5	0
531	MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.. <i>European Journal of Cancer</i> , 2022 , 167, 32-41	7.5	0
530	Explainable artificial intelligence in skin cancer recognition: A systematic review.. <i>European Journal of Cancer</i> , 2022 , 167, 54-69	7.5	6
529	Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 , 36 Suppl 1, 41-44	4.6	
528	CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.. <i>New England Journal of Medicine</i> , 2022 , 386, 1668-1669	59.2	1
527	Persister state-directed transitioning and vulnerability in melanoma. <i>Nature Communications</i> , 2022 , 13,	17.4	5
526	TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.. <i>European Journal of Cancer</i> , 2021 , 161, 99-107	7.5	0
525	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	2

524	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 159, 113-124	7.5	0
523	SIRT1-mediated deacetylation of FOXO3a transcription factor supports pro-angiogenic activity of interferon-deficient tumor-associated neutrophils. <i>International Journal of Cancer</i> , 2021 ,	7.5	2
522	Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. <i>BMC Cancer</i> , 2021 , 21, 1244	4.8	0
521	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
520	Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. <i>European Journal of Cancer</i> , 2021 ,	7.5	
519	High-resolution three-dimensional imaging for precise staging in melanoma. <i>European Journal of Cancer</i> , 2021 , 159, 182-193	7.5	0
518	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.. <i>European Journal of Cancer</i> , 2021 , 162, 22-33	7.5	2
517	Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. <i>Journal of Medical Internet Research</i> , 2021 , 23, e20708	7.6	10
516	30 years German Dermatologic Cooperative Oncology Group (DeCOG). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 1682-1697	1.2	
515	Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. <i>European Journal of Cancer</i> , 2021 , 158, 225-233	7.5	3
514	30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 1682-1697	1.2	
513	Fortschritte bei Systemtherapie verbessern Prognose. <i>Der Deutsche Dermatologe</i> , 2021 , 69, 826-837	0	
512	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 765608	5.3	1
511	Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. <i>European Journal of Cancer</i> , 2021 , 158, 72-84	7.5	3
510	Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. <i>Nature Genetics</i> , 2021 , 53, 332-341	36.3	22
509	Robustness of convolutional neural networks in recognition of pigmented skin lesions. <i>European Journal of Cancer</i> , 2021 , 145, 81-91	7.5	8
508	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. <i>Lancet Oncology</i> , 2021 , 22, 370-380	21.7	21
507	Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma 2021 , 9,		14

506	Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation-Induced DNA Damage and Melanoma Susceptibility. <i>Cancer Research</i> , 2021 , 81, 2956-2969	10.1	0
505	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021 , 39, 944-946	2.2	
504	Merkel-Zell-Karzinom. <i>Onkologe</i> , 2021 , 27, 569-578	0.1	0
503	GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors. <i>Frontiers in Genetics</i> , 2021 , 12, 663272	4.5	5
502	Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9561-9561	2.2	1
501	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9507-9507	2.2	6
500	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 655-664	21.7	9
499	Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification. <i>European Journal of Cancer</i> , 2021 , 149, 94-101	7.5	10
498	Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study. <i>Cancers</i> , 2021 , 13,	6.6	3
497	Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities. <i>European Journal of Cancer</i> , 2021 , 148, 395-404	7.5	5
496	Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology. <i>European Journal of Cancer</i> , 2021 , 148, 340-347	7.5	2
495	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. <i>Frontiers in Oncology</i> , 2021 , 11, 672172	5.3	1
494	Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9545-9545	2.2	5
493	Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9532-9532	2.2	2
492	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021 , 148, 61-75	7.5	5
491	Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1678-1685	4.6	1
490	CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9506-9506	2.2	29
489	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9503-9503	2.2	49

488	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 643-654	21.7	58
487	Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases. <i>European Journal of Cancer</i> , 2021 , 150, 119-129	7.5	
486	Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular Tumors. <i>Dermato</i> , 2021 , 1, 18-25		
485	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. <i>Cytokine and Growth Factor Reviews</i> , 2021 , 59, 1-8	17.9	2
484	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. <i>Clinical Cancer Research</i> , 2021 , 27, 4500-4510	12.9	4
483	Classical and Variant Merkel Cell Carcinoma Cell Lines Display Different Degrees of Neuroendocrine Differentiation and Epithelial-Mesenchymal Transition. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1675-1686.e4	4.3	3
482	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. <i>European Journal of Cancer</i> , 2021 , 152, 139-154	7.5	4
481	Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. <i>European Journal of Cancer</i> , 2021 , 152, 41-48	7.5	5
480	Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist. <i>Annals of Translational Medicine</i> , 2021 , 9, 1172	3.2	
479	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. <i>Cancers</i> , 2021 , 13,	6.6	2
478	The predictive and prognostic significance of cell-free DNA concentration in melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 387-395	4.6	7
477	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021 , 124, 574-580	8.7	9
476	Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. <i>European Journal of Cancer</i> , 2021 , 143, 43-45	7.5	1
475	BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1635-1647	7.4	4
474	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 1763-1771	4.9	0
473	Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53. <i>Oncogene</i> , 2021 , 40, 980-996	9.2	11
472	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition 2021 , 9,		20
471	Mutations in the IFN γ /JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. <i>Clinical Cancer Research</i> , 2021 , 27, 3432-3442	12.9	10

470	Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma. <i>Cancers</i> , 2021 , 13,	6.6	4
469	Mental Health Burden of German Cancer Patients before and after the Outbreak of COVID-19: Predictors of Mental Health Impairment. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	6
468	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021 , 152, 116-128	7.5	2
467	Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. <i>European Heart Journal</i> , 2021 ,	9.5	14
466	EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. <i>Annals of Oncology</i> , 2021 , 32, 1332-1347	10.3	29
465	Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis 2021 , 9,		7
464	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021 , 9, 1202-1213	12.5	11
463	Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. <i>European Journal of Cancer</i> , 2021 , 153, 234-241	7.5	4
462	Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity. <i>Cancer Immunology Research</i> , 2021 , 9, 1298-1315	12.5	1
461	Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. <i>Frontiers in Oncology</i> , 2021 , 11, 725549	5.3	1
460	Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic Merkel cell carcinoma. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	4
459	The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. <i>European Journal of Cancer</i> , 2021 , 155, 268-280	7.5	11
458	Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study. <i>European Journal of Cancer</i> , 2021 , 154, 167-174	7.5	5
457	Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. <i>European Journal of Cancer</i> , 2021 , 154, 227-234	7.5	7
456	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021 , 11, 741993	5.3	1
455	Response to comment - Molecular pathology as a diagnostic aid in difficult to classify melanocytic tumours with spitzoid morphology. <i>European Journal of Cancer</i> , 2021 , 157, 514-515	7.5	
454	A benchmark for neural network robustness in skin cancer classification. <i>European Journal of Cancer</i> , 2021 , 155, 191-199	7.5	6
453	Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. <i>European Journal of Cancer</i> , 2021 , 156, 202-216	7.5	16

452	Melanoma Differentiation Trajectories Determine Sensitivity toward Pre-Existing CD8 Tumor-Infiltrating Lymphocytes. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2480-2489	4.3	0
451	Malignes Melanom. <i>Onkologe</i> , 2020 , 26, 713-720	0.1	
450	Effect of a Face-Aging Mobile App-Based Intervention on Skin Cancer Protection Behavior in Secondary Schools in Brazil: A Cluster-Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 737-745	5.1	10
449	Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma. <i>European Journal of Cancer</i> , 2020 , 132, 176-186	7.5	7
448	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020 , 395, 1558-1568	4.0	100
447	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020 , 133, 94-103	7.5	8
446	Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG 2020 , 8,		7
445	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2543-2551	2.2	13
444	Oncocardiology: new challenges, new opportunities. <i>Herz</i> , 2020 , 45, 619-625	2.6	0
443	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. <i>European Journal of Cancer</i> , 2020 , 135, 1-7	7.5	12
442	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 2020 , 8,		19
441	Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses: a prospective, randomized and rater-blinded study (ACTICAP). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e844-e846	4.6	3
440	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing 2020 , 8,		53
439	Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective. <i>Frontiers in Medicine</i> , 2020 , 7, 233	4.9	19
438	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020 , 130, 126-138	7.5	39
437	Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. <i>Nature Communications</i> , 2020 , 11, 1335	17.4	33
436	Salivary cortisol levels and anxiety in melanoma patients undergoing sentinel lymph node excision under local anesthesia versus general anesthesia: a prospective study. <i>World Journal of Surgical Oncology</i> , 2020 , 18, 53	3.4	1
435	Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1. <i>Cell Death and Disease</i> , 2020 , 11, 496	9.8	6

434	Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102060	14.4	9
433	GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. <i>British Journal of Dermatology</i> , 2020 , 183, 928-939	4	12
432	Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain. <i>Frontiers in Immunology</i> , 2020 , 11, 120	8.4	15
431	Reply to the letter to the editor: 'Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images'. <i>European Journal of Cancer</i> , 2020 , 130, 262-264	7.5	1
430	Retraction Note to: cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca homeostasis in melanoma cells. <i>Cellular and Molecular Life Sciences</i> , 2020 , 77, 963	10.3	
429	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , 2020 , 577, 561-565	56.4	542
428	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 2257-2267	12.9	18
427	Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. <i>Lancet Oncology</i> , 2020 , 21, 294-305	21.7	154
426	Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. <i>European Journal of Cancer</i> , 2020 , 131, 18-26	7.5	26
425	Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study. <i>Journal of Dermatology</i> , 2020 , 47, 629-635	1.6	9
424	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020 , 52, 494-504	36.3	39
423	Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e526-e529	4.6	1
422	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy 2020 , 8,		13
421	308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma 2020 , 8, A335-A335		1
420	Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4266-4281	15.9	15
419	Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600E mutant melanoma: Five-year analysis of COMBI-AD.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10001-10001	2.2	15
418	Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10018-10018	2.2	21
417	The antiPD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600E mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10028-10028	2.2	7

416	Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10034-10034	2.2	1
415	The antiPD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600E mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 57-57	2.2	3
414	Effects of Label Noise on Deep Learning-Based Skin Cancer Classification. <i>Frontiers in Medicine</i> , 2020 , 7, 177	4.9	11
413	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600E mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 39-39	2.2	
412	The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. <i>Recent Results in Cancer Research</i> , 2020 , 214, 169-187	1.5	6
411	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 358-372	21.7	49
410	Malignes Melanom. <i>Onkologe</i> , 2020 , 26, 75-90	0.1	
409	Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2020 , 31, 144-152	10.3	36
408	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. <i>European Journal of Cancer</i> , 2020 , 126, 33-44	7.5	74
407	Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF mutation-positive melanoma receiving adjuvant vemurafenib. <i>Annals of Oncology</i> , 2020 , 31, 153-159	10.3	14
406	ER-aminopeptidase 1 determines the processing and presentation of an immunotherapy-relevant melanoma epitope. <i>European Journal of Immunology</i> , 2020 , 50, 270-283	6.1	2
405	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 519-527	13.4	148
404	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020 , 125, 114-120	7.5	29
403	Metabolic heterogeneity confers differences in melanoma metastatic potential. <i>Nature</i> , 2020 , 577, 115-120	5.4	141
402	Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity. <i>Cancer Research</i> , 2020 , 80, 798-810	10.1	12
401	Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. <i>JAMA Oncology</i> , 2020 , 6, 1957-1966	13.4	15
400	Five-Year Outcomes With Nivolumab in Patients With Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3937-3946	2.2	39
399	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients 2020 , 8,		19

398	The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. <i>European Journal of Cancer</i> , 2020 , 138, 68-76	7.5	6
397	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020 , 26, 1557-1563	50.5	41
396	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 1256-1264	12.4	27
395	Melanoma brain metastases - Interdisciplinary management recommendations 2020. <i>Cancer Treatment Reviews</i> , 2020 , 89, 102083	14.4	25
394	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1944-1956	4.6	46
393	1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone. <i>Annals of Oncology</i> , 2020 , 31, S734-S735	10.3	3
392	Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report. <i>Frontiers in Oncology</i> , 2020 , 10, 592609	5.3	3
391	Integrated molecular drivers coordinate biological and clinical states in melanoma. <i>Nature Genetics</i> , 2020 , 52, 1373-1383	36.3	11
390	LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600E-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. <i>Annals of Oncology</i> , 2020 , 31, S1172	10.3	36
389	COVID-19-Related Fear and Health-Related Safety Behavior in Oncological Patients. <i>Frontiers in Psychology</i> , 2020 , 11, 1984	3.4	41
388	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020 , 383, 1139-1148	59.2	105
387	Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma Regression. <i>Frontiers in Immunology</i> , 2020 , 11, 1849	8.4	7
386	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3925-3936	2.2	78
385	Fatal swelling of the groin - Clear cell sarcoma: a rare but important differential diagnosis to malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 1165-1168	1.2	0
384	Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2020 , 3,	3.6	10
383	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 2146-2156.e4	4.3	9
382	Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology. <i>PLoS Pathogens</i> , 2020 , 16, e1008340	7.6	6
381	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 119, 168-178	7.5	32

380	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019 , 29, 846-861	24.7	91
379	Superior skin cancer classification by the combination of human and artificial intelligence. <i>European Journal of Cancer</i> , 2019 , 120, 114-121	7.5	103
378	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
377	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019 , 109, 61-69	7.5	18
376	B-type natriuretic peptides for the prediction of cardiovascular events and mortality in patients living with HIV: Results from the HIV-HEART study. <i>International Journal of Cardiology</i> , 2019 , 281, 127-132	3.2	1
375	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 207-215	7.5	26
374	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. <i>Cell Reports</i> , 2019 , 27, 3573-3586.e7	10.6	36
373	Pathologist-level classification of histopathological melanoma images with deep neural networks. <i>European Journal of Cancer</i> , 2019 , 115, 79-83	7.5	82
372	Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors? 2019 , 7, 141		10
371	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 626-636	59.2	489
370	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 148-157	7.5	42
369	MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 983-990	7.4	44
368	Frequent Occurrence of and Mutations in Human Acral Naevi. <i>Cancers</i> , 2019 , 11,	6.6	6
367	Immunotherapy in non-melanoma skin cancer: updates and new perspectives. <i>Drugs in Context</i> , 2019 , 8, 212583	5.2	5
366	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. <i>Cancer Research</i> , 2019 , 79, 2947-2961	10.1	37
365	The prognostic value of sentinel lymph nodes on distant metastasis-free survival in patients with high-risk squamous cell carcinoma. <i>European Journal of Cancer</i> , 2019 , 111, 107-115	7.5	5
364	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 701-710	21.7	23
363	A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. <i>European Journal of Cancer</i> , 2019 , 111, 148-154	7.5	115

362	Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial. <i>Trials</i> , 2019 , 20, 99	2.8	4
361	Reply to E. Hindle and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1356-1358	2.2	1
360	Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. <i>European Journal of Cancer</i> , 2019 , 113, 47-54	7.5	174
359	Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology. <i>European Journal of Cancer</i> , 2019 , 112, 29-31	7.5	12
358	Sources of information and support for melanoma patients: differences between patients' and clinicians' preferences. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019 , 17, 652-654	1.2	3
357	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 867-875	2.2	135
356	Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. <i>European Journal of Cancer</i> , 2019 , 111, 30-37	7.5	58
355	Sequence-dependent cross-resistance of combined radiotherapy plus BRAF inhibition in melanoma. <i>European Journal of Cancer</i> , 2019 , 109, 137-153	7.5	11
354	Unmet information needs of patients with melanoma in Germany. <i>Melanoma Research</i> , 2019 , 29, 196-204	3.3	6
353	NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils. <i>International Journal of Cancer</i> , 2019 , 144, 136-149	7.5	30
352	Quality, Readability, and Understandability of German Booklets Addressing Melanoma Patients. <i>Journal of Cancer Education</i> , 2019 , 34, 760-767	1.8	7
351	Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2019 , 2, e198890	10.4	40
350	Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. <i>European Journal of Cancer</i> , 2019 , 119, 18-29	7.5	22
349	Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data. <i>European Journal of Cancer</i> , 2019 , 119, 30-34	7.5	20
348	Assessment of Nonradioactive Multispectral Optoacoustic Tomographic Imaging With Conventional Lymphoscintigraphic Imaging for Sentinel Lymph Node Biopsy in Melanoma. <i>JAMA Network Open</i> , 2019 , 2, e199020	10.4	14
347	Deep neural networks are superior to dermatologists in melanoma image classification. <i>European Journal of Cancer</i> , 2019 , 119, 11-17	7.5	101
346	Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. <i>European Journal of Cancer</i> , 2019 , 119, 57-65	7.5	66
345	Clinical and genetic analysis of melanomas arising in acral sites. <i>European Journal of Cancer</i> , 2019 , 119, 66-76	7.5	15

344	Merkelzellkarzinom. <i>Best Practice Onkologie</i> , 2019 , 14, 312-323		0
343	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019 , 119, 97-106	7.5	27
342	Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images. <i>European Journal of Cancer</i> , 2019 , 118, 91-96	7.5	90
341	Informations- und Hilfsangebote für Melanompatienten: Präferenzielle Unterschiede zwischen Patienten und Ärzten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019 , 17, 652-654	1.2	1
340	Prognostic factors for pulmonary metastasectomy in malignant melanoma: size matters. <i>European Journal of Cardio-thoracic Surgery</i> , 2019 , 56, 1104-1109	3	3
339	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , 2019 , 20, e378-e389	21.7	88
338	Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 2506-2516.e10	4.3	13
337	An Animal Model of Cutaneous Cyst Development Enables the Identification of Three Quantitative Trait Loci, Including the Homologue of a Human Locus (TRICY1). <i>Journal of Investigative Dermatology</i> , 2019 , 139, 2235-2238.e5	4.3	
336	Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting. <i>Annals of Oncology</i> , 2019 , 30, v543-v544	10.3	2
335	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 121, 144-153	7.5	19
334	Health-related quality of life in patients with fully resected BRAF mutation-positive melanoma receiving adjuvant vemurafenib. <i>European Journal of Cancer</i> , 2019 , 123, 155-161	7.5	2
333	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma 2019 ,		12
332	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600E mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9515-9515	2.2	1
331	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600E mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9531-9531	2.2	26
330	Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9568-9568	2.2	
329	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 765-772	7.4	23
328	Complex Formation with Monomeric β -Tubulin and Importin 13 Fosters c-Jun Protein Stability and Is Required for c-Jun's Nuclear Translocation and Activity. <i>Cancers</i> , 2019 , 11,	6.6	3
327	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019 , 25, 1916-1927	50.5	227

326	Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies 2019 , 7, 343		24
325	Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. <i>Annals of Oncology</i> , 2019 , 30, 317-324	10.3	7
324	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. <i>JAMA Oncology</i> , 2019 , 5, 187-194	13.4	173
323	Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal and infections-a cross-sectional, single-center study. <i>Sexually Transmitted Infections</i> , 2019 , 95, 95-98	3.8	5
322	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 510-520	21.7	123
321	Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. <i>Clinical Chemistry</i> , 2018 , 64, 830-842	5.5	34
320	A skin cancer prevention photoageing intervention for secondary schools in Brazil delivered by medical students: protocol for a randomised controlled trial. <i>BMJ Open</i> , 2018 , 8, e018299	3	9
319	STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon- γ <i>Melanoma Research</i> , 2018 , 28, 204-210	3.3	6
318	Dose-dependent toxicity of ipilimumab in metastatic melanoma. <i>European Journal of Cancer</i> , 2018 , 95, 104-108	7.5	4
317	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1789-1801	59.2	918
316	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. <i>European Journal of Cancer</i> , 2018 , 96, 34-43	7.5	59
315	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , 2018 , 173, 624-633.e8	56.2	71
314	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , 2018 , 19, 310-322	21.7	284
313	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018 , 91, 116-124	7.5	54
312	Intraventricular melanocytoma diagnosis confirmed by gene mutation profile. <i>Neuropathology</i> , 2018 , 38, 288-292	2	4
311	Sebaceous tumours: more than skin deep. <i>Gut</i> , 2018 , 67, 1957	19.2	0
310	Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 677-681	9.7	33
309	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 603-615	21.7	451

308	Evolution of melanoma cross-resistance to CD8 T cells and MAPK inhibition in the course of BRAFi treatment. <i>Onc Immunology</i> , 2018 , 7, e1450127	7.2	11
307	NF1 mutations in conjunctival melanoma. <i>British Journal of Cancer</i> , 2018 , 118, 1243-1247	8.7	43
306	Postsurgical Treatment of Split Skin Graft Donor Sites in Dermatological Departments. <i>International Journal of Lower Extremity Wounds</i> , 2018 , 17, 22-29	1.6	3
305	Oxygenation Status in Chronic Leg Ulcer After Topical Hemoglobin Application May Act as a Surrogate Marker to Find the Best Treatment Strategy and to Avoid Ineffective Conservative Long-term Therapy. <i>Molecular Imaging and Biology</i> , 2018 , 20, 124-130	3.8	7
304	Actinic keratoses treated with cold atmospheric plasma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e37-e39	4.6	30
303	The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 73-87	4.1	24
302	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5873-5882	12.9	35
301	Patient-reported outcomes with nivolumab in advanced solid cancers. <i>Cancer Treatment Reviews</i> , 2018 , 70, 75-87	14.4	11
300	Phase I, open-label study of pasireotide in patients with wild type and -wild type, unresectable and/or metastatic melanoma. <i>ESMO Open</i> , 2018 , 3, e000388	6	4
299	Facial-Aging App Availability in Waiting Rooms as a Potential Opportunity for Skin Cancer Prevention. <i>JAMA Dermatology</i> , 2018 , 154, 1085-1086	5.1	11
298	Willingness to pay for a cure of low-risk melanoma patients in Germany. <i>PLoS ONE</i> , 2018 , 13, e0197780	3.7	6
297	Information-seeking and use of information resources among melanoma patients of German skin cancer centers. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018 , 16, 1093-1101	1.2	5
296	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018 , 50, 1271-1281	36.3	249
295	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , 2018 , 101, 236-243	7.5	59
294	Fear of cancer progression in patients with stage IA malignant melanoma. <i>European Journal of Cancer Care</i> , 2018 , 27, e12901	2.4	9
293	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018 , 379, 341-351	59.2	659
292	PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E5766-E5775	11.5	10
291	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018 , 24, 5347-5356	12.9	140

290	Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. <i>European Journal of Cancer</i> , 2018 , 99, 58-65	7.5	7
289	Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 2093-2102	8.8	10
288	Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. <i>Clinical Cancer Research</i> , 2018 , 24, 4494-4504	12.9	14
287	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9504-9504	2.2	19
286	Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9519-9519	2.2	2
285	Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9527-9527	2.2	14
284	Adverse events of special interest in the phase 3 COLUMBUS study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9567-9567	2.2	2
283	Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9574-9574	2.2	1
282	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9590-9590	2.2	7
281	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9591-9591	2.2	8
280	The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. <i>Oncotarget</i> , 2018 , 9, 26217-26225	3.3	3
279	A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic. <i>Journal of Medical Internet Research</i> , 2018 , 20, e10976	7.6	11
278	Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing. <i>Journal of Medical Internet Research</i> , 2018 , 20, e11871	7.6	17
277	Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. <i>Journal of Medical Internet Research</i> , 2018 , 20, e11936	7.6	14
276	A Skin Cancer Prevention Facial-Aging Mobile App for Secondary Schools in Brazil: Appearance-Focused Interventional Study. <i>JMIR MHealth and UHealth</i> , 2018 , 6, e60	5.5	17
275	Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3074-3074	2.2	1
274	Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3036-3036	2.2	
273	Neue Arzneimittel lassen hoffen. <i>Der Deutsche Dermatologe</i> , 2018 , 66, 604-617	0	

272	Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles. <i>Modern Pathology</i> , 2018 , 31, 418-428	9.8	38
271	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018 , 91, 168-170	7.5	23
270	PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. <i>European Journal of Cancer</i> , 2018 , 88, 67-76	7.5	13
269	Intraoperative use of LIGHTVISION: a novel fluorescence navigation system using indocyanine green for sentinel lymph node biopsy in skin cancer patients. <i>European Journal of Dermatology</i> , 2018 , 28, 532-534	0.8	
268	Reply to M. Horiguchi et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 721	2.2	1
267	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 383-390	2.2	273
266	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3441-3449	2.2	137
265	Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. <i>Annals of Oncology</i> , 2018 , 29, viii446	10.3	2
264	Merkelzellkarzinom. <i>Onkologe</i> , 2018 , 24, 1037-1049	0.1	
263	Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. <i>Lancet Oncology, The</i> , 2018 , 19, e720-e725	21.7	23
262	Predictors of quality of life in melanoma patients 4 years after diagnosis: Results of a nationwide cohort study in Germany. <i>Journal of Psychosocial Oncology</i> , 2018 , 36, 734-753	2.8	2
261	Re: van Poppelen et al.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912). <i>Ophthalmology</i> , 2018 , 125, e78-e79	7.3	2
260	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018 , 175, 984-997.e24	56.2	477
259	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1480-1492	21.7	680
258	Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk. <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 564-572	5	24
257	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1315-1327	21.7	291
256	Melanoma. <i>Lancet, The</i> , 2018 , 392, 971-984	40	516
255	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. <i>European Journal of Cancer</i> , 2018 , 98, 10-16	7.5	34

254	Role of Elevated Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2018 , 24, 4119-4125	12.9	5
253	IRF4 rs12203592 functional variant and melanoma survival. <i>International Journal of Cancer</i> , 2017 , 140, 1845-1849	7.5	11
252	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 75, 47-55	7.5	99
251	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 435-445	21.7	240
250	Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. <i>Nature Communications</i> , 2017 , 8, 14447	17.4	12
249	Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 404-412	21.7	108
248	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017 , 73, 61-70	7.5	59
247	Metastatic recurrence of 17-year relapse-free melanoma during anti-TNF α therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e368-e369	4.6	
246	SF3B1 and BAP1 mutations in blue nevus-like melanoma. <i>Modern Pathology</i> , 2017 , 30, 928-939	9.8	57
245	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017 , 28, 1631-1639	10.3	361
244	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. <i>Annals of Oncology</i> , 2017 , 28, 1380-1387	10.3	85
243	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. <i>BMC Cancer</i> , 2017 , 17, 332	4.8	196
242	Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2033-2035	4.3	20
241	S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017 , 15, e1-e41	1.2	19
240	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017 , 82, 45-55	7.5	114
239	Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. <i>Nature Communications</i> , 2017 , 8, 15440	17.4	125
238	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 611-622	21.7	306
237	Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. <i>Annals of Oncology</i> , 2017 , 28, 634-641	10.3	124

236	Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi. <i>Modern Pathology</i> , 2017 , 30, 350-356	9.8	44
235	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 785-792	2.2	696
234	Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. <i>European Journal of Cancer</i> , 2017 , 71, 53-69	7.5	217
233	Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. <i>European Journal of Cancer</i> , 2017 , 86, 248-256	7.5	43
232	Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma 2017 , 58, 3464-3470		27
231	Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. <i>Annals of Oncology</i> , 2017 , 28, v429-v430	10.3	23
230	Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone. <i>Annals of Oncology</i> , 2017 , 28, v428	10.3	22
229	Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. <i>Oncotarget</i> , 2017 , 8, 40683-40692	3.3	53
228	A smoking prevention photoageing intervention for secondary schools in Brazil delivered by medical students: protocol for a randomised trial. <i>BMJ Open</i> , 2017 , 7, e018589	3	10
227	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3807-3814	2.2	264
226	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 641-650	7.1	6
225	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. <i>European Journal of Cancer</i> , 2017 , 83, 247-257	7.5	181
224	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017 , 8, 592	17.4	122
223	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1813-1823	59.2	778
222	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
221	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. <i>Oncolimmunology</i> , 2017 , 6, e1338237	7.2	36
220	Update on the clinical use of kinase inhibitors in melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017 , 15, 887-893	1.2	7
219	Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. <i>European Journal of Cancer</i> , 2017 , 83, 142-145	7.5	4

218	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , 2017 , 32, 204-220.e15	24.3	391
217	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. <i>Cancer Research</i> , 2017 , 77, 4697-4709	10.1	87
216	Checkpointinhibitoren. <i>Onkologe</i> , 2017 , 23, 619-625	0.1	
215	Update der S3-Leitlinie zum malignen Melanom. <i>Best Practice Onkologie</i> , 2017 , 12, 110-119	0	1
214	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017 , 77, 4684-4696	10.1	67
213	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. <i>JAMA Oncology</i> , 2017 , 3, 1511-1519	13.4	101
212	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017 , 82, 80-91	7.5	55
211	Immunotherapy in melanoma: Recent advances and future directions. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 604-611	3.6	167
210	Melanoma diagnosed in lesions previously treated by laser therapy. <i>Journal of Dermatology</i> , 2017 , 44, 23-28	1.6	16
209	Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior antiPD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. <i>Annals of Oncology</i> , 2017 , 28, 611-619	10.3	64
208	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 37-45	7.5	106
207	Trametinib-Induced Remission of an -Mutated Langerhans Cell Histiocytosis.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-5	3.6	5
206	Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC) 2017 ,		81
205	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067) 2017 ,		26
204	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9524-9524	2.2	14
203	Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9526-9526	2.2	5
202	PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9527-9527	2.2	2
201	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 641-650	7.1	5

200	Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq. <i>Oncotarget</i> , 2017 , 8, 846-862	3.3	54
199	Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma. <i>Oncotarget</i> , 2017 , 8, 23760-23774	3.3	14
198	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model. <i>Oncotarget</i> , 2017 , 8, 28312-28327	3.3	17
197	Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. <i>Oncotarget</i> , 2017 , 8, 79731-79741	3.3	59
196	A Medical Student-Delivered Smoking Prevention Program, Education Against Tobacco, for Secondary Schools in Germany: Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2017 , 19, e199	7.6	15
195	Photoaging Mobile Apps in School-Based Melanoma Prevention: Pilot Study. <i>Journal of Medical Internet Research</i> , 2017 , 19, e319	7.6	18
194	A Dermatologist's Ammunition in the War Against Smoking: A Photoaging App. <i>Journal of Medical Internet Research</i> , 2017 , 19, e326	7.6	9
193	Photoaging Mobile Apps as a Novel Opportunity for Melanoma Prevention: Pilot Study. <i>JMIR MHealth and UHealth</i> , 2017 , 5, e101	5.5	22
192	Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. <i>European Journal of Cancer</i> , 2016 , 67, 66-72	7.5	79
191	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , 2016 , 17, 1743-1754	21.7	205
190	Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes. <i>Scientific Reports</i> , 2016 , 6, 24032	4.9	69
189	PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. <i>Annals of Oncology</i> , 2016 , 27, vi381	10.3	11
188	Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis. <i>Medicine (United States)</i> , 2016 , 95, e4332	1.8	23
187	Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K mutant cutaneous melanoma. <i>Annals of Oncology</i> , 2016 , 27, vi575	10.3	26
186	Preferences of German melanoma patients for interferon (IFN) α b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy. <i>Medicine (United States)</i> , 2016 , 95, e5375	1.8	8
185	Phenotypic characterization and prognostic impact of circulating α and β T-cells in metastatic malignant melanoma. <i>International Journal of Cancer</i> , 2016 , 138, 698-704	7.5	22
184	Adjuvant treatment with pegylated interferon α versus low-dose interferon α in patients with high-risk melanoma: a randomized phase III DeCOG trial. <i>Annals of Oncology</i> , 2016 , 27, 1625-32	10.3	15
183	Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. <i>Cancer Research</i> , 2016 , 76, 4347-58	10.1	42

182	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 2908-18	12.9	372
181	Oncogene status as a diagnostic tool in ocular and cutaneous melanoma. <i>European Journal of Cancer</i> , 2016 , 57, 112-7	7.5	13
180	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016 , 351, 1463-9	33.3	1758
179	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016 , 53, 125-34	7.5	115
178	Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2016 , 127, 435-44	4.8	41
177	Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. <i>Clinical Cancer Research</i> , 2016 , 22, 567-74	12.9	151
176	Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9505-9505	2.2	40
175	Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA. <i>Oncotarget</i> , 2016 , 7, 59115-59128	3.3	13
174	SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma. <i>Oncotarget</i> , 2016 , 7, 10117-32	3.3	12
173	Proportions of blood-borne V α 1+ and V α 2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016 , 64, 116-26	7.5	36
172	Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. <i>International Journal of Cancer</i> , 2016 , 139, 1297-302	7.5	10
171	High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 598-600	4.5	20
170	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. <i>Science Translational Medicine</i> , 2016 , 8, 369ra177	17.5	14
169	Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS). <i>Scientific Reports</i> , 2016 , 6, 25208	4.9	15
168	Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. <i>European Journal of Cancer</i> , 2016 , 59, 109-112	7.5	37
167	Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation Signature. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1526-1528	4.3	6
166	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016 , 22, 5487-5496	12.9	373
165	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016 , 532, 250-4	50.4	205

164	Photoacoustic imaging of real-time oxygen changes in chronic leg ulcers after topical application of a haemoglobin spray: a pilot study. <i>Journal of Wound Care</i> , 2016 , 25, 87, 89-91	2.2	31
163	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016 , 60, 210-25	7.5	391
162	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016 , 60, 190-209	7.5	412
161	Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe. <i>European Journal of Cancer</i> , 2016 , 60, 179-89	7.5	39
160	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 4848-4858	12.9	108
159	Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma?. <i>Lancet Oncology, The</i> , 2016 , 17, 1337-1339	21.7	12
158	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016 , 67, 46-54	7.5	54
157	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. <i>Oncologist</i> , 2016 , 21, 1230-1240	5.7	165
156	Nivolumab in previously untreated melanoma without BRAF mutation. <i>New England Journal of Medicine</i> , 2015 , 372, 320-30	59.2	3809
155	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015 , 161, 1681-96	56.2	1807
154	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. <i>Nature Genetics</i> , 2015 , 47, 987-995	36.3	162
153	A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. <i>Annals of Oncology</i> , 2015 , 26, 573-82	10.3	17
152	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 908-18	21.7	1151
151	Response. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	
150	Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. <i>European Journal of Cancer</i> , 2015 , 51, 653-67	7.5	36
149	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 833-40	7.5	60
148	Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al. <i>Annals of Oncology</i> , 2015 , 26, 250-251	10.3	1
147	CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. <i>Cancer Research</i> , 2015 , 75, 1897-907	10.1	19

146	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15003	51.1	283
145	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1889-94	2.2	1425
144	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , 2015 , 16, 1389-98	21.7	162
143	Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4077-84	2.2	21
142	Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. <i>Lancet Oncology</i> , 2015 , 16, e522-6	21.7	17
141	Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies: prospective randomized clinical trial to compare ICG-(99m)Tc-nanocolloid hybrid tracer versus (99m)Tc-nanocolloid. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1431-1438	8.8	59
140	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. <i>Clinical Cancer Research</i> , 2015 , 21, 5453-9	12.9	237
139	Intraoperative Fluorescence Imaging for Sentinel Lymph Node Detection: Prospective Clinical Trial to Compare the Usefulness of Indocyanine Green vs Technetium Tc 99m for Identification of Sentinel Lymph Nodes. <i>JAMA Surgery</i> , 2015 , 150, 617-23	5.4	69
138	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015 , 350, 207-211	33.3	1583
137	Therapie des malignen Melanoms. <i>Onkologe</i> , 2015 , 21, 965-976	0.1	
136	Improved overall survival in melanoma with combined dabrafenib and trametinib. <i>New England Journal of Medicine</i> , 2015 , 372, 30-9	59.2	1723
135	3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 8463	7.5	44
134	Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. <i>Experimental Dermatology</i> , 2015 , 24, 155-7	4	24
133	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015 , 13, 351	8.5	47
132	MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 736-40	4.5	12
131	Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells: A live-cell RNAi screen displays differential nucleus-derived phenotypes. <i>Biotechnology Journal</i> , 2015 , 10, 1467-77	5.6	3
130	Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia 2015 , 56, 5854-61		16
129	CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. <i>Frontiers in Oncology</i> , 2015 , 5, 234	5.3	7

128	Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. <i>PLoS ONE</i> , 2015 , 10, e0118564	3.7	155
127	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. <i>Oncotarget</i> , 2015 , 6, 36041-52	3.3	71
126	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
125	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 444-51	4.0	926
124	Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. <i>Science Translational Medicine</i> , 2015 , 7, 317ra199	17.5	183
123	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015 , 51, 2792-9	7.5	202
122	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology, The</i> , 2015 , 16, 15-7	21.7	9
121	Panel sequencing melanomas. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 335-336	4.3	3
120	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA1-LBA1	2.2	9
119	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA1-LBA1	2.2	18
118	Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection. <i>PLoS ONE</i> , 2015 , 10, e0124590	3.7	7
117	Analysis of SDHD promoter mutations in various types of melanoma. <i>Oncotarget</i> , 2015 , 6, 25868-82	3.3	8
116	The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment Differences between the patient's and the physician's perspective.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20099-e20099	2.2	
115	Primary tumor versus metastasis: new experimental models for studies on cancer cell homing and metastasis in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 309-16	4.5	5
114	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1877-88	59.2	1195
113	Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1723-31	8.8	32
112	Malignes Melanom. <i>Onkologe</i> , 2014 , 20, 530-532	0.1	
111	Medikamentöse Systemtherapie des Melanoms. <i>Onkologe</i> , 2014 , 20, 568-576	0.1	2

110	Behandlungsalgorithmus bei Patienten mit malignem Melanom. <i>Onkologe</i> , 2014 , 20, 533-534	0.1	
109	TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	164
108	Melanoma in 2013: Melanoma--the run of success continues. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 75-6	19.4	59
107	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , 2014 , 15, 323-32	21.7	753
106	Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance. <i>European Journal of Cell Biology</i> , 2014 , 93, 49-54	6.1	22
105	Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. <i>European Journal of Cancer</i> , 2014 , 50, 774-83	7.5	116
104	Reply to M. Perier-Muzet et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3203	2.2	2
103	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. <i>Modern Pathology</i> , 2014 , 27, 175-83	9.3	66
102	Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. <i>Annals of Oncology</i> , 2014 , 25, 747-753	10.3	42
101	Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. <i>Clinical Cancer Research</i> , 2014 , 20, 1601-9	12.9	192
100	Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. <i>Annals of Oncology</i> , 2014 , 25, 700-706	10.3	40
99	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. <i>Cancer Discovery</i> , 2014 , 4, 94-109	24.4	626
98	Genetic evolution of T-cell resistance in the course of melanoma progression. <i>Clinical Cancer Research</i> , 2014 , 20, 6593-604	12.9	106
97	Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. <i>British Journal of Dermatology</i> , 2014 , 171, 1099-107	4	117
96	The impact of the immune system on tumor: angiogenesis and vascular remodeling. <i>Frontiers in Oncology</i> , 2014 , 4, 69	5.3	105
95	TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. <i>Modern Pathology</i> , 2014 , 27, 502-8	9.8	81
94	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology</i> , 2014 , 15, 297-304	21.7	49
93	Genetic alterations and personalized medicine in melanoma: progress and future prospects. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt435	9.7	57

92	Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9031-9031	2.2	2
91	BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. <i>Chinese Clinical Oncology</i> , 2014 , 3, 29	2.3	33
90	Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9062-9062	2.2	
89	TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. <i>British Journal of Cancer</i> , 2013 , 109, 497-501	8.7	91
88	Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not?. <i>European Radiology</i> , 2013 , 23, 2622-7	8	14
87	Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. <i>International Journal of Cancer</i> , 2013 , 133, 1653-63	7.5	99
86	Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3205-11	2.2	343
85	TERT promoter mutations in familial and sporadic melanoma. <i>Science</i> , 2013 , 339, 959-61	33.3	1261
84	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. <i>Lancet Oncology, The</i> , 2013 , 14, 249-56	21.7	487
83	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. <i>Lancet Oncology, The</i> , 2013 , 14, 733-40	21.7	135
82	Intracerebral metastases of malignant melanoma and their recurrences--a clinical analysis. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115, 1721-8	2	10
81	Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. <i>Clinical Cancer Research</i> , 2013 , 19, 3143-52	12.9	150
80	Conjunctival melanomas harbor BRAF and NRAS mutations--response. <i>Clinical Cancer Research</i> , 2013 , 19, 6331-2	12.9	15
79	Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. <i>Clinical Cancer Research</i> , 2013 , 19, 2232-9	12.9	117
78	TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 17426-31	11.5	236
77	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. <i>Cancer Medicine</i> , 2013 , 2, 76-85	4.8	102
76	Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11 Suppl 6, 1-116, 1-126	1.2	79
75	S3-Leitlinie „Diagnostik, Therapie und Nachsorge des Melanoms“Kurzfassung. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11, 563-594	1.2	4

74	S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11, 563-602	1.2	29
73	The genetic landscape of clinical resistance to RAF inhibition in melanoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11009-11009	2.2	1
72	Treatment of Distant and Irresectable Metastatic Disease 2013 , 79-104		
71	Side effects of systemic oncological therapies in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012 , 10, 475-86	1.2	11
70	Melanoma genome sequencing reveals frequent PREX2 mutations. <i>Nature</i> , 2012 , 485, 502-6	50.4	555
69	Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1007-14	27.4	97
68	Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. <i>European Journal of Cancer</i> , 2012 , 48, 218-25	7.5	146
67	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2012 , 13, 1087-95	21.7	708
66	Immuntherapie des Melanoms. <i>Onkologe</i> , 2012 , 18, 801-807	0.1	
65	A landscape of driver mutations in melanoma. <i>Cell</i> , 2012 , 150, 251-63	56.2	1799
64	Improved survival with MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2012 , 367, 107-14	59.2	1634
63	Indocyanine green fluorescence-guided sentinel lymph node biopsy in dermato-oncology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012 , 10, 51-7	1.2	13
62	Fluoreszenz-Markierung mittels Indocyanin-Grün bei der Sentinel-Lymphknoten-Exstirpation in der Dermatoonkologie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012 , 10, 51-58	1.2	10
61	Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2375-83	2.2	175
60	Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3810-8	2.2	204
59	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. <i>Journal of Clinical Oncology</i> , 2012 , 30, 316-21	2.2	318
58	The efficiency of human cytomegalovirus pp65(495-503) CD8+ T cell epitope generation is determined by the balanced activities of cytosolic and endoplasmic reticulum-resident peptidases. <i>Journal of Immunology</i> , 2012 , 189, 529-38	5.3	20
57	Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. <i>Archives of Dermatology</i> , 2012 , 148, 357-61		79

56	Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?. <i>Molecular Oncology</i> , 2011 , 5, 137-49	7.9	36
55	A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. <i>European Journal of Cancer</i> , 2011 , 47, 1977-89	7.5	47
54	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). <i>European Journal of Cancer</i> , 2011 , 47, 1476-83	7.5	157
53	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
52	Reliability and cost-effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma: a retrospective analysis in 300 patients with malignant melanoma AJCC Stages I and II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 306-10	4.6	18
51	Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1213-21	4.6	44
50	Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. <i>Cancer</i> , 2011 , 117, 1697-703	6.4	98
49	A randomised, phase II study of intetumumab, an anti- α -integrin mAb, alone and with dacarbazine in stage IV melanoma. <i>British Journal of Cancer</i> , 2011 , 105, 346-52	8.7	91
48	Sorafenib and pegylated interferon- α 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. <i>Annals of Oncology</i> , 2011 , 22, 1667-1674	10.3	23
47	EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon- α 2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 8506b-8506b	2.2	10
46	Predictors of sun protection behaviors and severe sunburn in an international online study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2199-210	4	91
45	PLX4032: does it keep its promise for metastatic melanoma treatment?. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1439-49	5.9	20
44	Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 841-6	2.2	65
43	Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. <i>Journal of Experimental Medicine</i> , 2010 , 207, 491-503	16.6	151
42	Improved survival with ipilimumab in patients with metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 711-23	59.2	10591
41	Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. <i>Lancet Oncology</i> , 2010 , 11, 155-64	21.7	910
40	cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells. <i>Cellular and Molecular Life Sciences</i> , 2010 , 67, 817-28	10.3	29
39	Diagnostik des malignen Melanoms. <i>Onkologe</i> , 2010 , 16, 1121-1130	0.1	

38	Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. <i>Seminars in Oncology</i> , 2010 , 37, 485-98	5.5	130
37	Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2823-30	2.2	456
36	Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2916-23	2.2	88
35	Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. <i>Clinical Cancer Research</i> , 2009 , 15, 1384-92	12.9	151
34	Immunotherapy of distant metastatic disease. <i>Annals of Oncology</i> , 2009 , 20 Suppl 6, vi41-50	10.3	40
33	Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytotoxicity of MHC class I-deficient melanoma by natural killer cells. <i>International Journal of Cancer</i> , 2009 , 124, 1594-604	7.5	72
32	Palliative Therapie des malignen Melanoms im Stadium IV. <i>Onkologe</i> , 2009 , 15, 767-776	0.1	
31	Peroxisome proliferator-activating receptors: a new way to treat melanoma?. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 1061-3	4.3	9
30	Proteomics for biomarker discovery in malignant melanoma. <i>Expert Review of Dermatology</i> , 2008 , 3, 209-220		6
29	Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). <i>Annals of Oncology</i> , 2008 , 19, 801-6	10.3	21
28	Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. <i>Melanoma Research</i> , 2008 , 18, 152-60	3.3	50
27	Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. <i>Cancer</i> , 2008 , 113, 1404-11	6.4	18
26	Short German guidelines: malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008 , 6 Suppl 1, S9-S14	1.2	68
25	B-Raf and N-Ras mutations are preserved during short time in vitro propagation and differentially impact prognosis. <i>PLoS ONE</i> , 2007 , 2, e236	3.7	107
24	Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. <i>Clinical Cancer Research</i> , 2007 , 13, 6344-50	12.9	57
23	Evidence and interdisciplinary consensus-based German guidelines: diagnosis and surveillance of melanoma. <i>Melanoma Research</i> , 2007 , 17, 393-9	3.3	98
22	Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. <i>Annals of Oncology</i> , 2006 , 17, 1592-7	10.3	40
21	Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. <i>Annals of Oncology</i> , 2006 , 17, 563-70	10.3	342

20	In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. <i>Clinical Cancer Research</i> , 2006 , 12, 5454-63	12.9	74
19	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. <i>Pigment Cell & Melanoma Research</i> , 2006 , 19, 290-302		378
18	Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 8030-8030	2.2	2
17	A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 8044-8044	2.2	14
16	Utilizing Artificial Neural Networks to Elucidate Serum Biomarker Patterns Which Discriminate Between Clinical Stages in Melanoma 2005 ,		1
15	Lack of clinical efficacy of imatinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2005 , 92, 1398-4058.	7	224
14	Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9001-7	2.2	95
13	Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6747-55	2.2	146
12	Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. <i>European Journal of Cancer</i> , 2004 , 40, 390-402	7.5	182
11	Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) as first-line treatment of patients with metastatic melanoma: Results of a prospective-randomized phase III study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 7508-7508	2.2	5
10	Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. <i>Strahlentherapie Und Onkologie</i> , 2003 , 179, 366-71	4.3	36
9	Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2883-8	2.2	54
8	Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. <i>European Journal of Cancer</i> , 2002 , 38, 1501-11	7.5	49
7	Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 158-66	2.2	961
6	The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. <i>British Journal of Cancer</i> , 1999 , 79, 1025-31	8.7	120
5	Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. <i>Journal of Clinical Oncology</i> , 1997 , 15, 2579-88	2.2	172
4	Skin Cancer Classification using Convolutional Neural Networks: Systematic Review (Preprint)		4
3	Persister state-directed transitioning and vulnerability in melanoma		1

2	High-resolution 3-D imaging for precise staging in malignant melanoma	2
1	Multi-modal pooled Perturb-CITE-Seq screens in patient models define novel mechanisms of cancer immune evasion	3